Adocia
ISIN: FR0011184241 | Ticker: ADOC | LEI: 969500ZL79KYH9PTYP78
Country: France
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases.
In the diabetes field, Adocia’s portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring five clinical-stage products. Additionally, Adocia aims to expand its portfolio towards the treatment of other metabolic diseases and their comorbidities.
The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application.
2005
Served areaWorldwide
Headquarters115 Avenue Lacassagne, 69003 Lyon – France
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 45,166,000.00 | 30,054,000.00 | 30,613,000.00 |
| Noncurrent Assets | N/A | 8,720,000.00 | 1,073,000.00 | 4,353,000.00 |
| Land | N/A | 2,032,000.00 | 0.00 | 0.00 |
| Buildings | N/A | 3,298,000.00 | 0.00 | 2,050,000.00 |
| Other Property Plant And Equipment | N/A | 2,502,000.00 | 642,000.00 | 492,000.00 |
| Goodwill | N/A | 0.00 | 0.00 | 0.00 |
| Other Intangible Assets | N/A | 46,000.00 | 3,000.00 | 32,000.00 |
| Current Assets | N/A | 36,446,000.00 | 22,084,000.00 | 26,260,000.00 |
| Current Trade Receivables | N/A | 0.00 | 207,000.00 | 467,000.00 |
| Cash and cash equivalents | 43,661,000.00 | 28,114,000.00 | 15,163,000.00 | 17,422,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | N/A | 0.00 | 6,897,000.00 | 0.00 |
| Other Current Assets | N/A | 7,763,000.00 | 6,197,000.00 | 8,234,000.00 |
| Equity And Liabilities | N/A | 45,166,000.00 | 30,054,000.00 | 30,613,000.00 |
| Equity | N/A | 6,334,000.00 | -13,815,000.00 | -12,970,000.00 |
| Issued Capital | N/A | 702,000.00 | 727,000.00 | 873,000.00 |
| Share Premium | N/A | 78,731,000.00 | 80,562,000.00 | 86,123,000.00 |
| Noncurrent Liabilities | N/A | 28,110,000.00 | 20,115,000.00 | 18,506,000.00 |
| Other Noncurrent Liabilities | N/A | 715,000.00 | 309,000.00 | 0.00 |
| Current Liabilities | N/A | 10,723,000.00 | 23,754,000.00 | 25,077,000.00 |
| Trade And Other Current Payables | N/A | 4,943,000.00 | 3,835,000.00 | 6,414,000.00 |
| Other Current Liabilities | N/A | 2,766,000.00 | 3,724,000.00 | 2,992,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 841,000.00 | 1,444,000.00 | 11,447,000.00 |
| Depreciation And Amortisation Expense | 1,133,000.00 | 1,158,000.00 | 496,000.00 |
| Profit Loss From Operating Activities | -21,148,000.00 | -19,366,000.00 | -1,698,000.00 |
| Finance Income | 103,000.00 | 220,000.00 | 573,000.00 |
| Finance Costs | 2,250,000.00 | 3,608,000.00 | 5,300,000.00 |
| Profit Loss Before Tax | -23,295,000.00 | -22,754,000.00 | -6,425,000.00 |
| Income Tax Expense Continuing Operations | 29,000.00 | 0.00 | 476,000.00 |
| Profit (loss) | -23,324,000.00 | -22,754,000.00 | -6,901,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -23,324,000.00 | -22,754,000.00 | -6,901,000.00 |
| Adjustments For Income Tax Expense | N/A | 0.00 | 0.00 | 0.00 |
| Other Adjustments For Noncash Items | N/A | 2,650,000.00 | 4,791,000.00 | 13,045,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | N/A | 53,000.00 | 27,000.00 | -16,560,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -21,854,000.00 | -19,234,000.00 | -14,995,000.00 |
| Other Inflows Outflows Of Cash Classified As Investing Activities | N/A | 0.00 | 0.00 | 0.00 |
| Cash Flows From Used In Investing Activities | N/A | -204,000.00 | -361,000.00 | 21,864,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 7,000,000.00 | 6,000,000.00 | 6,000,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 488,000.00 | 398,000.00 | 10,611,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | N/A | 0.00 | 0.00 | 0.00 |
| Cash Flows From Used In Financing Activities | N/A | 6,512,000.00 | 6,644,000.00 | -4,611,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -15,547,000.00 | -12,951,000.00 | 2,259,000.00 |
| Cash and cash equivalents | 43,661,000.00 | 28,114,000.00 | 15,163,000.00 | 17,422,000.00 |
Please note that some sums might not add up.
FR0011184241
LEI969500ZL79KYH9PTYP78
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.